

Rapid Review References

1. [Schultes RE. Hallucinogens of plant origin. *Science*. 1969;163\(3864\):245-254.](#)
2. [Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: their sacred. *Healing, and Hallucinogenic Powers \(Healing Arts, Rochester, VT\)*. 2001.](#)
3. [Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. *J Psychopharmacol*. 2008;22\(6\):603-620.](#)
4. [Guzmán G. The hallucinogenic mushrooms: diversity, traditions, use and abuse with special reference to the genus *Psilocybe*. In: *Fungi from different environments*. CRC Press; 2019:256-277.](#)
5. [Araujo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. *Arch Toxicol*. 2015;89\(8\):1151-1173.](#)
6. [Krippner S, Winkelman M. Maria Sabina: Wise lady of the mushrooms. *J Psychoactive Drugs*. 1983;15\(3\):225-228.](#)
7. [Tricco AC, Langlois EV, Straus SE, editors. Rapid reviews to strengthen health policy and systems: a practical guide. In. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO; 2017.](#)
8. [Castro Santos H, Gama Marques J. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. *Porto biomed*. 2021;6\(1\):e128.](#)
9. [Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*. 2016;30\(12\):1181-1197.](#)
10. [Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. 2011;68\(1\):71-78.](#)
11. [Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*. 2016;30\(12\):1165-1180.](#)
12. [Carhart-Harris R, Bolstridge M, Day C, et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. *Psychopharmacology \(Berl\)*. 2018;235\(2\):399-408.](#)
13. [Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry*. 2016;3\(7\):619-627.](#)
14. [Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *J Psychopharmacol*. 2014;28\(11\):983-992.](#)
15. [Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *The American Journal of Drug and Alcohol Abuse*. 2017;43\(1\):55-60.](#)
16. [Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *Journal of psychopharmacology \(oxford, england\)*. 2015;29\(3\):289-299.](#)
17. [Moreno FA, Wiegand CB, Taitano E, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *The Journal of Clinical Psychiatry*. 2006;67\(11\):1735-1740.](#)
18. [Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. *Psychiatry Res*. 2020;284:112749.](#)

19. [Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. *EClinicalMedicine*. 2020;27:100538.](#)
20. [Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2021;78\(5\):481-489.](#)
21. [Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. *N Engl J Med*. 2021;384\(15\):1402-1411.](#)
22. [Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. *Neurother*. 2020;12:12.](#)
23. [Vehling S, Kissane DW, Lo C, et al. The association of demoralization with mental disorders and suicidal ideation in patients with cancer. *Cancer*. 2017;123\(17\):3394-3401.](#)
24. [Varker T, Watson L, Gibson K, Forbes D, O'Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. *J Psychoactive Drugs*. 2021;53\(1\):85-95.](#)
25. [Williams MT, Davis AK, Xin Y, et al. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. *Drugs: Education, Prevention and Policy*. 2021;28\(3\):215-226.](#)
26. [Vargas AS, Luis A, Barroso M, Gallardo E, Pereira L. Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials. *Biomedicines*. 2020;8\(9\):05.](#)
27. [Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology \(Berl\)*. 2006;187\(3\):268-283; discussion 284-292.](#)
28. [Hood J, Ralph W, Ghorbani N, Watson PJ, et al. Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. *J Sci Study Relig*. 2001;40\(4\):691-705.](#)
29. [Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. *Neurosci Biobehav Rev*. 2020;113:179-189.](#)
30. [Erritzoe D, Roseman L, Nour MM, et al. Effects of psilocybin therapy on personality structure. *Acta Psychiatr Scand*. 2018;138\(5\):368-378.](#)
31. [Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. *J Psychopharmacol*. 2018;32\(1\):49-69.](#)
32. [Madsen MK, Fisher PM, Stenbæk DS, et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT_{2A} receptor binding. *Eur Neuropsychopharmacol*. 2020;33:71-80.](#)
33. [Dahmane E, Hutson PR, Gobburu JVS. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. *Clin*. 2021;10\(1\):78-85.](#)
34. [Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. *Psychopharmacology \(Berl\)*. 2018;235\(10\):2915-2927.](#)
35. [Johnson MW, Sewell R, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. *Drug and Alcohol Dependence*. 2012;123\(1-3\):132-140.](#)
36. [Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. *Psychopharmacology \(Berl\)*. 2004;172\(2\):145-156.](#)

37. [Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *J Psychopharmacol.* 2016;30\(12\):1268-1278.](#)
38. [Galvao-Coelho NL, Marx W, Gonzalez M, et al. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. *Psychopharmacology \(Berl\).* 2021;238\(2\):341-354.](#)
39. [Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients' accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression. *Journal of Humanistic Psychology.* 2017;57\(5\):520-564.](#)
40. [Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. *J Psychopharmacol.* 2018;32\(7\):756-769.](#)
41. [Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *J Psychopharmacol.* 2011;25\(11\):1434-1452.](#)
42. [Benjamin C. Persistent psychiatric symptoms after eating psilocybin mushrooms. *Br Med J.* 1979;1\(6174\):1319-1320.](#)
43. [Ken Gillman P. Triptans, serotonin agonists, and serotonin syndrome \(serotonin toxicity\): a review. *Headache: The Journal of Head and Face Pain.* 2010;50\(2\):264-272.](#)
44. [Suzuki K. \[Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning\]. *Chudoku Kenkyu.* 2016;29\(1\):33-35.](#)
45. [Martinotti G, Santacrose R, Pettoruso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. *Brain sciences.* 2018;8\(3\):47.](#)
46. [Espiard M-L, Lecardeur L, Abadie P, Halbecq I, Dollfus S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. *European psychiatry.* 2005;20\(5-6\):458-460.](#)
47. [Dittrich A, von Arx S, Staub S. Concerning the question of increased readiness to consume hallucinogens subsequent to experiments with hallucinogens. *Schweizerische Zeitschrift für Psychologie und ihre Anwendungen/Revue suisse de Psychologie pure et appliquée.* 1980.](#)
48. [Nichols DE. Psychedelics. *Pharmacol Rev.* 2016;68\(2\):264-355.](#)
49. [Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. *PLoS ONE.* 2012;7\(2\):e30800.](#)
50. [Leptourgos P, Fortier-Davy M, Carhart-Harris R, et al. Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. *Schizophrenia Bulletin.* 2020;46\(6\):1396-1408.](#)
51. [Beug MW, Bigwood J. Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A. *J Ethnopharmacol.* 1982;5\(3\):271-285.](#)
52. [van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. *Regul Toxicol Pharmacol.* 2011;59\(3\):423-429.](#)
53. [Fricke J, Sherwood A, Kargbo R, et al. Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin. *Chembiochem.* 2019;20\(22\):2824-2829.](#)
54. [Sherwood AM, Halberstadt AL, Klein AK, et al. Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. *J Nat Prod.* 2020;83\(2\):461-467.](#)
55. [Beck O, Helander A, Karlson-Stiber C, Stephansson N. Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. *J Anal Toxicol.* 1998;22\(1\):45-49.](#)

56. [Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V. Hallucinogen persisting perception disorder: A literature review and three case reports. *J Addict Dis.* 2018;37\(3-4\):268-278.](#)
57. [Leonard JB, Anderson B, Klein-Schwartz W. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. *J Psychopharmacol.* 2018;32\(12\):1286-1294.](#)
58. [Muller K, Puschel K, Iwersen-Bergmann S. \[Suicide under the influence of "magic mushrooms"\]. *Arch Kriminol.* 2013;231\(5-6\):193-198.](#)
59. [Lim TH, Wasywich CA, Ruygrok PN. A fatal case of 'magic mushroom' ingestion in a heart transplant recipient. *Intern Med J.* 2012;42\(11\):1268-1269.](#)
60. [Johansen P-O, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: A population study. *J Psychopharmacol.* 2015;29\(3\):270-279.](#)
61. [Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *J Psychopharmacol.* 2015;29\(3\):280-288.](#)
62. [Hendricks PS, Crawford MS, Cropsey KL, et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population. *J Psychopharmacol.* 2018;32\(1\):37-48.](#)
63. [Bienemann B, Ruschel NS, Campos ML, Negreiros MA, Mograbi DC. Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. *PLoS ONE.* 2020;15\(2\):e0229067.](#)
64. [Barrett FS, Johnson MW, Griffiths RR. Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Pers Individ Dif.* 2017;117:155-160.](#)
65. [Carrillo F, Sigman M, Fernandez Slezak D, et al. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. *J Affect Disord.* 2018;230:84-86.](#)
66. [Reynolds HT, Vijayakumar V, Gluck-Thaler E, Korotkin HB, Matheny PB, Slot JC. Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. *Evol.* 2018;2\(2\):88-101.](#)
67. [Blei F, Baldeweg F, Fricke J, Hoffmeister D. Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions. *Chemistry.* 2018;11:11.](#)
68. [Blei F, Fricke J, Wick J, Slot JC, Hoffmeister D. Iterative L-Tryptophan Methylation in Psilocybe Evolved by Subdomain Duplication. *Chembiochem.* 2018;19\(20\):2160-2166.](#)
69. [Fricke J, Blei F, Hoffmeister D. Enzymatic Synthesis of Psilocybin. *Angew Chem Int Ed Engl.* 2017;56\(40\):12352-12355.](#)
70. [Fricke J, Kargbo R, Regestein L, et al. Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. *Chemistry.* 2020;26\(37\):8281-8285.](#)
71. [Torrens-Spence MP, Liu CT, Pluskal T, Chung YK, Weng JK. Monoamine Biosynthesis via a Noncanonical Calcium-Activatable Aromatic Amino Acid Decarboxylase in Psilocybin Mushroom. *ACS Chem Biol.* 2018;13\(12\):3343-3353.](#)
72. [Demmler R, Fricke J, Dorner S, Gressler M, Hoffmeister D. S-Adenosyl-L-Methionine Salvage Impacts Psilocybin Formation in "Magic" Mushrooms. *Chembiochem.* 2020;21\(9\):1364-1371.](#)
73. [Lenz C, Sherwood A, Kargbo R, Hoffmeister D. Taking Different Roads: L-Tryptophan as the Origin of Psilocybe Natural Products. *ChemPlusChem.* 2021;86\(1\):28-35.](#)
74. [Reingardiene D, Vilcinskaite J, Lazauskas R. \[Hallucinogenic mushrooms\]. *Medicina \(Kaunas\).* 2005;41\(12\):1067-1070.](#)
75. [Lincoff G, Mitchel DH. *Toxic and hallucinogenic mushroom poisoning. A handbook for physicians and mushroom hunters.* Van Nostrand Reinhold Company.; 1977.](#)
76. [Stamets P. *Psilocybin mushrooms of the world.* Ten Speed Press; 1996.](#)

77. [Schafer AT. \[Microscopic study of powders of hallucinogenic mushrooms--Psilocybe sp\]. *Arch Kriminol.* 2000;205\(1-2\):30-36.](#)
78. [Uehling JK, Henkel TW, Aime MC, Vilgalys R, Smith ME. New species and distribution records for Clavulina \(Cantharellales, Basidiomycota\) from the Guiana Shield, with a key to the lowland neotropical taxa. *Fungal biology.* 2012;116\(12\):1263-1274.](#)
79. [Lenz C, Wick J, Braga D, et al. Injury-Triggered Blueing Reactions of Psilocybe "Magic" Mushrooms. *Angew Chem Int Ed Engl.* 2020;59\(4\):1450-1454.](#)
80. [Franz M, Regele H, Kirchmair M, et al. Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. *Nephrol Dial Transplant.* 1996;11\(11\):2324-2327.](#)
81. [Adams AM, Kaplan NA, Wei Z, et al. In vivo production of psilocybin in *E. coli*. *Metab Eng.* 2019;56:111-119.](#)
82. [Milne N, Thomsen P, Molgaard Knudsen N, Rubaszka P, Kristensen M, Borodina I. Metabolic engineering of *Saccharomyces cerevisiae* for the de novo production of psilocybin and related tryptamine derivatives. *Metab Eng.* 2020;60:25-36.](#)
83. [Fricke J, Lenz C, Wick J, Blei F, Hoffmeister D. Production Options for Psilocybin: Making of the Magic. *Chemistry.* 2019;25\(4\):897-903.](#)
84. [Guzmán G. Hallucinogenic mushrooms in Mexico: An overview. *Economic Botany.* 2008;62\(3\):404-412.](#)
85. [Guzmán G. New taxonomical and ethnomycological observations on psilocybe ss \(fungi, basidiomycota, agaricomycetidae, agaricales, strophariaceae\) from Mexico, Africa and Spain. *Acta botánica mexicana.* 2012\(100\):79-106.](#)
86. [Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. Liquid chromatography-mass spectrometric and liquid chromatography-tandem mass spectrometric determination of hallucinogenic indoles psilocin and psilocybin in "magic mushroom" samples. *J Forensic Sci.* 2005;50\(2\):336-340.](#)
87. [Stribny J, Borovicka J, Sokol M. \[Levels of psilocybin and psilocin in various types of mushrooms\]. *Soud Lek.* 2003;48\(3\):45-49.](#)
88. [Saito K, Toyo'oka T, Kato M, Fukushima T, Shirota O, Goda Y. Determination of psilocybin in hallucinogenic mushrooms by reversed-phase liquid chromatography with fluorescence detection. *Talanta.* 2005;66\(3\):562-568.](#)
89. [Sottolano SM, Lurie IS. The quantitation of psilocybin in hallucinogenic mushrooms using high performance liquid chromatography. *J Forensic Sci.* 1983;28\(4\):929-935.](#)
90. [Christiansen AL, Rasmussen KE. Screening of hallucinogenic mushrooms with high-performance liquid chromatography and multiple detection. *J Chromatogr.* 1983;270:293-299.](#)
91. [Beug MW, Bigwood J. Quantitative analysis of psilocybin and psilocin in psilocybe baeocystis \(Singer and Smith\) by high-performance liquid chromatography and by thin-layer chromatography. *J Chromatogr.* 1981;207\(3\):379-385.](#)
92. [Stahl E, Brombeer J, Eskes D. \[Narcotic mushrooms with LSD?\]. *Arch Kriminol.* 1978;162\(1-2\):23-33.](#)
93. [Hofmann A, et al. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexicanischen Rauschpilzen. *Helvetica Chimica Acta* 1959;42:1557-1572](#)
94. [Van Orden RC. *Determination of psilocybin and psilocin in hallucinogenic mushrooms by HPLC with diode array and MS detection.* State University of New York College of Environmental Science and Forestry; 2008.](#)
95. [Stebelska K. Assays for Detection of Fungal Hallucinogens Such as Psilocybin and Psilocin. In: *Neuropathology of Drug Addictions and Substance Misuse.* Elsevier; 2016:909-926.](#)
96. [Nagy J, Veress T. HPLC analysis of hallucinogenic mushroom alkaloids \(psilocin and psilocybin\) applying hydrophilic interaction chromatography \(HILIC\). *Journal of Forensic Research.* 2016;7\(6\):10.4172.](#)

97. [Rácz N, Nagy J, Jiang W, Veress T. Modeling retention behavior on analysis of hallucinogenic mushrooms using hydrophilic interaction liquid chromatography. *J Chromatogr Sci.* 2019;57\(3\):230-237.](#)
98. [Veress T, Rácz N, Nagy J, Jiang W. Determination of Psilocin and Psilocybin in Magic Mushrooms Using iHILIC®-Fusion and MS. In: ADVANSTAR COMMUNICATIONS INC 131 W 1ST STREET, DULUTH, MN 55802 USA; 2020.](#)
99. [Zhou L, Xiang P, Wen D, et al. Sensitive quantitative analysis of psilocin and psilocybin in hair samples from suspected users and their distribution in seized hallucinogenic mushrooms. *Forensic Toxicology.* 2021:1-10.](#)
100. [Anastos N, Lewis SW, Barnett NW, Sims DN. The determination of psilocin and psilocybin in hallucinogenic mushrooms by HPLC utilizing a dual reagent acidic potassium permanganate and tris\(2,2'-bipyridyl\)ruthenium\(II\) chemiluminescence detection system. *J Forensic Sci.* 2006;51\(1\):45-51.](#)
101. [Gambaro V, Roda G, Visconti GL, et al. Taxonomic Identification of Hallucinogenic Mushrooms Seized on the Illegal Market Using a DNA-Based Approach and LC/MS-MS Determination of Psilocybin and Psilocin. 2015.](#)
102. [Stamets P, Chilton J. The mushroom cultivator. *First Washington.* 1983.](#)
103. [Lambert EB. Principles and problems of mushroom culture. *The Botanical Review.* 1938;4\(7\):397.](#)
104. [Evans HJ, Hughes DT, Thomas PT. Chemically induced neoplasms in fungi. *Nature.* 1956;178\(4540\):949-951.](#)
105. [Moore D. Principles of mushroom developmental biology. *International Journal of Medicinal Mushrooms.* 2005;7\(1&2\).](#)
106. [Bressa G, Cima L, Costa P. Bioaccumulation of Hg in the mushroom *Pleurotus ostreatus*. *Ecotoxicology and environmental safety.* 1988;16\(2\):85-89.](#)
107. [Gabriel J, Vosahlo J, Baldrian P. Biosorption of cadmium to mycelial pellets of wood-rotting fungi. *Biotechnology Techniques.* 1996;10\(5\):345-348.](#)
108. [Tüzen M, Özdemir M, Demirbaş A. Heavy metal bioaccumulation by cultivated *Agaricus bisporus* from artificially enriched substrates. *Zeitschrift für Lebensmitteluntersuchung und-Forschung A.* 1998;206\(6\):417-419.](#)
109. [Michelot D, Siobud E, Doré J-C, Viel C, Poirier F. Update on metal content profiles in mushrooms—toxicological implications and tentative approach to the mechanisms of bioaccumulation. *Toxicon.* 1998;36\(12\):1997-2012.](#)
110. [Falandysz J, Szymczyk K, Ichihashi H, et al. ICP/MS and ICP/AES elemental analysis \(38 elements\) of edible wild mushrooms growing in Poland. *Food Additives & Contaminants.* 2001;18\(6\):503-513.](#)
111. [Demirbaş A. Concentrations of 21 metals in 18 species of mushrooms growing in the East Black Sea region. *Food Chemistry.* 2001;75\(4\):453-457.](#)
112. [Demirbaş A. Heavy metal bioaccumulation by mushrooms from artificially fortified soils. *Food chemistry.* 2001;74\(3\):293-301.](#)
113. [Demirbaş A. Metal ion uptake by mushrooms from natural and artificially enriched soils. *Food Chemistry.* 2002;78\(1\):89-93.](#)
114. [García MÁ, Alonso J, Melgar MJ. Lead in edible mushrooms: levels and bioaccumulation factors. *Journal of Hazardous Materials.* 2009;167\(1-3\):777-783.](#)
115. [Gabriel J, Švec K, Koliňová D, Tlustoš P, Száková J. Translocation of mercury from substrate to fruit bodies of *Panellus stipticus*, *Psilocybe cubensis*, *Schizophyllum commune* and *Stropharia rugosoannulata* on oat flakes. *Ecotoxicology and environmental safety.* 2016;125:184-189.](#)
116. [Širić I, Humar M, Kasap A, Kos I, Mioč B, Pohleven F. Heavy metal bioaccumulation by wild edible saprophytic and ectomycorrhizal mushrooms. *Environmental science and pollution research.* 2016;23\(18\):18239-18252.](#)

117. [Tel-Cayan G, Ullah Z, Ozturk M, Yabanli M, Aydin F, Duru ME. Heavy metals, trace and major elements in 16 wild mushroom species determined by ICP-MS. 2018.](#)
118. [Sener S. Effect of Seagrass Mixed With Casing Soil for the Cultivation of Mushrooms and Study of Bioaccumulation of Heavy Metals. *Atomic Spectroscopy*. 2019;40:188.](#)
119. [Chang Q, Fan C, Chen H, Kang J, Wang M, Pang G. Determination of 187 pesticide residues in edible fungi by liquid chromatography-tandem mass spectrometry. *Analytical Methods*. 2014;6\(12\):4288-4304.](#)
120. [Galgówska M, Pietrzak-Fiećko R. Pesticide contaminants in selected species of edible wild mushrooms from the north-eastern part of Poland Part B Pesticides, food contaminants, and agricultural wastes. 2017.](#)
121. [Du P, Wu X, Xu J, et al. Different residue behaviors of four pesticides in mushroom using two different application methods. *Environmental Science and Pollution Research*. 2018;25\(9\):8377-8387.](#)
122. [Tian F, Qiao C, Luo J, et al. Method development and validation of ten pyrethroid insecticides in edible mushrooms by Modified QuEChERS and gas chromatography-tandem mass spectrometry. *Sci*. 2020;10\(1\):1-10.](#)
123. [Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. *Neuropharmacology*. 2018;142:263-269.](#)
124. [Stauffer CS, Anderson BT, Ortigo KM, Woolley J. Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience. *ACS pharmacol*. 2021;4\(2\):526-532.](#)
125. [Dos Santos RG, Bouso JC, Alcazar-Corcoles MA, Hallak JEC. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. *Expert Rev Clin Pharmacol*. 2018;11\(9\):889-902.](#)
126. [Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *J Psychopharmacol*. 2020;34\(2\):155-166.](#)
127. [Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. *ACS pharmacol*. 2021;4\(2\):553-562.](#)
128. [Swift TC, Belser AB, Agin-Liebes G, et al. Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. *Journal of Humanistic Psychology*. 2017;57\(5\):488-519.](#)
129. [Malone TC, Mennenga SE, Guss J, et al. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. *Front Pharmacol*. 2018;9:256.](#)
130. [Strickland JC, Garcia-Romeu A, Johnson MW. Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy. *ACS pharmacol*. 2021;4\(2\):472-478.](#)
131. [Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. *Front Pharmacol*. 2018;9\(132\).](#)
132. [Bogenschutz MP, Podrebarac SK, Duane JH, et al. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. *Front Pharmacol*. 2018;9:100.](#)
133. [Borowiak KS, Ciechanowski K, Waloszczyk P. Psilocybin mushroom \(*Psilocybe semilanceata*\) intoxication with myocardial infarction. *J Toxicol Clin Toxicol*. 1998;36\(1-2\):47-49.](#)

134. [Steiner J, Sulman F. Simultaneous studies of blood sugar, behavioural changes and EEG on the wake rabbit after administration of psilocybin. *Archives internationales de pharmacodynamie et de therapie*. 1963;145:301-308.](#)
135. [Tyls F, Palenicek T, Horacek J. Psilocybin--summary of knowledge and new perspectives. *Eur Neuropsychopharmacol*. 2014;24\(3\):342-356.](#)
136. [Koivikko A, Savolainen J. Mushroom allergy. *Allergy*. 1988;43\(1\):1-10.](#)
137. [Raff E, Halloran PF, Kjellstrand CM. Renal failure after eating "magic" mushrooms. *Cmaj*. 1992;147\(9\):1339-1341.](#)
138. [Austin E, Myron HS, Summerbell RK, Mackenzie C. Acute renal injury cause by confirmed *Psilocybe cubensis* mushroom ingestion. *Med Mycol Case Rep*. 2019;23:55-57.](#)
139. [Gard DE, Pleet MM, Bradley ER, et al. Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies. *medRxiv*. 2021:2021.2004.2002.21254838.](#)
140. [Zeifman RJ, Singhal N, Breslow L, Weissman CR. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. *ACS pharmacol*. 2021;4\(2\):436-451.](#)
141. [Seiler N, Nguyen T, Yung A, O'Donoghue B. Terminology and assessment tools of psychosis: A systematic narrative review. *Psychiatry and clinical neurosciences*. 2020;74\(4\):226-246.](#)
142. [Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales \(DASS\) with the Beck Depression and Anxiety Inventories. *Behaviour research and therapy*. 1995;33\(3\):335-343.](#)
143. [Davis AK, Barrett FS, So S, Gukasyan N, Swift TC, Griffiths RR. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. *J Psychopharmacol*. 2021;35\(4\):437-446.](#)
144. [Kamata T, Nishikawa M, Katagi M, Tsuchihashi H. Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2003;796\(2\):421-427.](#)
145. [Shoda T, Fukuhara K, Goda Y, Okuda H. Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms. *Drug Test Anal*. 2011;3\(9\):594-596.](#)
146. [Poliwoda A, Zielinska K, Wieczorek PP. Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis. *Molecules \(Basel\)*. 2020;25\(7\):29.](#)
147. [Pichini S, Marchei E, Garcia-Algar O, Gomez A, Di Giovannandrea R, Pacifici R. Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers. *J Pharm Biomed Anal*. 2014;100:284-289.](#)
148. [Sticht G, Kaferstein H. Detection of psilocin in body fluids. *Forensic Sci Int*. 2000;113\(1-3\):403-407.](#)
149. [Morita I, Oyama H, Kiguchi Y, et al. Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms. *J Pharm Biomed Anal*. 2020;190:113485.](#)
150. [Racz N, Nagy J, Jiang W, Veress T. Modeling Retention Behavior on Analysis of Hallucinogenic Mushrooms Using Hydrophilic Interaction Liquid Chromatography. *J Chromatogr Sci*. 2019;57\(3\):230-237.](#)
151. [Gotvaldova K, Hajkova K, Borovicka J, Jurok R, Cihlarova P, Kuchar M. Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom *Psilocybe cubensis*. *Drug Test Anal*. 2021;13\(2\):439-446.](#)
152. [Musha M, Ishii A, Tanaka F, Kusano G. Poisoning by hallucinogenic mushroom hikageshibiretake \(*Psilocybe argentipes* K. Yokoyama\) indigenous to Japan. *Tohoku J Exp Med*. 1986;148\(1\):73-78.](#)

153. [Riley SC, Blackman G. Between prohibitions: patterns and meanings of magic mushroom use in the UK. *Subst Use Misuse*. 2008;43\(1\):55-71.](#)
154. [Peden NR, Pringle SD, Crooks J. The problem of psilocybin mushroom abuse. *Hum Toxicol*. 1982;1\(4\):417-424.](#)
155. [Forrester MB. Hallucinogenic mushroom misuse reported to Texas poison centers. *J Addict Dis*. 2020;38\(4\):482-488.](#)
156. [Satora L, Goszcz H, Ciszowski K. Poisonings resulting from the ingestion of magic mushrooms in Krakow. *Przeegl Lek*. 2005;62\(6\):394-396.](#)
157. [Manevski N, Kurkela M, Hoglund C, et al. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. *Drug Metab Dispos*. 2010;38\(3\):386-395.](#)
158. [Naz F, Jyoti S, Rahul, Akhtar N, Siddique YH. Effect of Oral Contraceptive Pills on the Blood Serum Enzymes and DNA Damage in Lymphocytes Among Users. *Indian J Clin Biochem*. 2016;31\(3\):294-301.](#)
159. Miners et al., 2017 – Citation pending
160. [Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. *Clin J Am Soc Nephrol*. 2009;4\(3\):673-679.](#)
161. [Veverka KA, Johnson KL, Mays DC, Lipsky JJ, Naylor S. Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. *Biochem Pharmacol*. 1997;53\(4\):511-518.](#)
162. [Honda M, Nishida T, Ono H. Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT\(2\) receptors. *Eur J Pharmacol*. 2003;458\(1-2\):91-99.](#)